Department of Radiation Oncology,
College of Medicine,
UF Health Cancer Center,
Department of Radiation Oncology, College of Medicine
Dietmar Siemann has not added Biography.
If you are Dietmar Siemann and would like to personalize this page please email our Author Liaison for assistance.
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
International journal of cancer May, 2002 | Pubmed ID: 11948484
Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma.
Acta oncologica (Stockholm, Sweden) , 2002 | Pubmed ID: 11990525
Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
International journal of radiation oncology, biology, physics May, 2002 | Pubmed ID: 12007956
Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo.
Cancer gene therapy Jun, 2002 | Pubmed ID: 12032662
Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
International journal of radiation oncology, biology, physics Dec, 2002 | Pubmed ID: 12459379
Enhancement of radiation therapy by vascular targeting agents.
Current opinion in investigational drugs (London, England : 2000) Nov, 2002 | Pubmed ID: 12476970
Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy.
Seminars in radiation oncology Jan, 2003 | Pubmed ID: 12520464
Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus.
Anticancer research Nov-Dec, 2002 | Pubmed ID: 12530082
Gene therapy delivery of endostatin enhances the treatment efficacy of radiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Jan, 2003 | Pubmed ID: 12559515
Postoperative radiation therapy for squamous cell carcinoma of the head and neck.
American journal of otolaryngology Jan-Feb, 2003 | Pubmed ID: 12579482
Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach.
Anticancer research Jan-Feb, 2004 | Pubmed ID: 15015599
Targeting the tumor vasculature: a strategy to improve radiation therapy.
Expert review of anticancer therapy Apr, 2004 | Pubmed ID: 15056061
Vascular-targeting therapies for treatment of malignant disease.
Cancer Jun, 2004 | Pubmed ID: 15197790
Therapeutic strategies that selectively target and disrupt established tumor vasculature.
Hematology/oncology clinics of North America Oct, 2004 | Pubmed ID: 15474333
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
International journal of radiation oncology, biology, physics Nov, 2004 | Pubmed ID: 15519796
Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Dec, 2004 | Pubmed ID: 15588883
Differentiation and definition of vascular-targeted therapies.
Clinical cancer research : an official journal of the American Association for Cancer Research Jan, 2005 | Pubmed ID: 15701823
The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
International journal of radiation oncology, biology, physics Jul, 2005 | Pubmed ID: 15936569
Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trial.
Cancer Jul, 2005 | Pubmed ID: 15937906
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
In vivo (Athens, Greece) Nov-Dec, 2005 | Pubmed ID: 16277020
Preclinical studies of the novel vascular disrupting agent MN-029.
Anticancer research Nov-Dec, 2005 | Pubmed ID: 16309177
Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma.
Anticancer research Jan-Feb, 2006 | Pubmed ID: 16475712
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
International journal of radiation oncology, biology, physics Jul, 2006 | Pubmed ID: 16751064
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2006 | Pubmed ID: 16818709
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
European journal of cancer (Oxford, England : 1990) Nov, 2006 | Pubmed ID: 16956760
Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.
Anticancer research Sep-Oct, 2006 | Pubmed ID: 17094465
Impact of VEGF expression on the physiological characteristics of clonal cell lines.
In vivo (Athens, Greece) Nov-Dec, 2006 | Pubmed ID: 17203773
Characterizing the tumor response to treatment with combretastatin A4 phosphate.
International journal of radiation oncology, biology, physics May, 2007 | Pubmed ID: 17448875
Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
European journal of cancer (Oxford, England : 1990) Jul, 2007 | Pubmed ID: 17451938
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.
Journal of immunology (Baltimore, Md. : 1950) Jul, 2008 | Pubmed ID: 18566400
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Anticancer research Jul-Aug, 2008 | Pubmed ID: 18751370
Vascular targeted therapies in oncology.
Cell and tissue research Jan, 2009 | Pubmed ID: 18752004
Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines.
American journal of veterinary research Sep, 2008 | Pubmed ID: 18764694
Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy.
American journal of veterinary research Jan, 2009 | Pubmed ID: 19119958
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
International journal of radiation oncology, biology, physics Mar, 2009 | Pubmed ID: 19215823
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Expert opinion on investigational drugs Feb, 2009 | Pubmed ID: 19236265
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas.
Translational oncology Mar, 2009 | Pubmed ID: 19252749
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
Anticancer research Jun, 2009 | Pubmed ID: 19528456
Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.
Blood Nov, 2009 | Pubmed ID: 19717647
In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503.
Oncology reports Mar, 2010 | Pubmed ID: 20127007
Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.
The Journal of urology May, 2010 | Pubmed ID: 20303530
Leukemia regression by vascular disruption and antiangiogenic therapy.
Blood Sep, 2010 | Pubmed ID: 20472832
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Molecular cancer therapeutics Jun, 2010 | Pubmed ID: 20515943
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.
Cancer treatment reviews Feb, 2011 | Pubmed ID: 20570444
Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Expert opinion on investigational drugs Nov, 2010 | Pubmed ID: 20964495
Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
Microvascular research Jan, 2011 | Pubmed ID: 20974154
Impact of hypoxia on the metastatic potential of human prostate cancer cells.
International journal of radiation oncology, biology, physics Oct, 2011 | Pubmed ID: 21640519
Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells.
Gene therapy Apr, 2012 | Pubmed ID: 21776025
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.
International journal of radiation biology Nov, 2011 | Pubmed ID: 21815749
Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation.
Proceedings of the National Academy of Sciences of the United States of America Sep, 2011 | Pubmed ID: 21896759
E-cadherin plasticity in prostate cancer stem cell invasion.
American journal of cancer research , 2011 | Pubmed ID: 21968440
Another road leads to HIF-1 activation: implications for prostate cancer progression.
Asian journal of andrology Mar, 2012 | Pubmed ID: 22101943
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Clinical & experimental metastasis Feb, 2012 | Pubmed ID: 22130962
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.
Clinical & experimental metastasis Mar, 2012 | Pubmed ID: 22286523
Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.
Microvascular research May, 2012 | Pubmed ID: 22387475
Src-signaling interference impairs the dissemination of blood-borne tumor cells.
Cell and tissue research Aug, 2012 | Pubmed ID: 22526632
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
BMC cancer May, 2012 | Pubmed ID: 22639908
Vascular development in mouse lung metastases.
American journal of cancer research , 2012 | Pubmed ID: 22957309
Cell-based selection provides novel molecular probes for cancer stem cells.
International journal of cancer Jun, 2013 | Pubmed ID: 23150432
Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.
Blood Jan, 2013 | Pubmed ID: 23212515
An update on the clinical development of drugs to disable tumor vasculature.
Expert opinion on drug discovery Oct, 2007 | Pubmed ID: 23484531
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells.
Neoplasia (New York, N.Y.) Apr, 2013 | Pubmed ID: 23555190
Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice.
American journal of veterinary research May, 2013 | Pubmed ID: 23627391
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells.
Clinical & experimental metastasis Oct, 2013 | Pubmed ID: 23748470
Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model.
Journal of applied physiology (Bethesda, Md. : 1985) Dec, 2013 | Pubmed ID: 24177690
Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model.
Anti-cancer drugs Mar, 2014 | Pubmed ID: 24304691
MRI-based computational model of heterogeneous tracer transport following local infusion into a mouse hind limb tumor.
PloS one , 2014 | Pubmed ID: 24619021
Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise.
Journal of the National Cancer Institute Apr, 2014 | Pubmed ID: 24627275
In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.
Biomedical optics express Jun, 2014 | Pubmed ID: 24940553
Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis.
Vascular cell , 2014 | Pubmed ID: 25101168
Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.
Cancer letters 10, 2016 | Pubmed ID: 25312939
Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer.
Molecular cancer research : MCR Mar, 2015 | Pubmed ID: 25373480
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Cancer letters Apr, 2015 | Pubmed ID: 25676691
Modulation of the tumor vasculature and oxygenation to improve therapy.
Pharmacology & therapeutics Sep, 2015 | Pubmed ID: 26073310
Cathepsin L targeting in cancer treatment.
Pharmacology & therapeutics Nov, 2015 | Pubmed ID: 26299995
Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.
Bioorganic & medicinal chemistry Nov, 2015 | Pubmed ID: 26462052
Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
International journal of cancer Jun, 2016 | Pubmed ID: 26757413
Chemosensitizing AML cells by targeting bone marrow endothelial cells.
Experimental hematology May, 2016 | Pubmed ID: 26898708
Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.
Clinical & experimental metastasis 06, 2016 | Pubmed ID: 27055649
Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation.
American journal of cancer research , 2016 | Pubmed ID: 27294000
Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.
The Journal of clinical investigation 11, 2016 | Pubmed ID: 27721239
Exercise and the Tumor Microenvironment: Potential Therapeutic Implications.
Exercise and sport sciences reviews 01, 2018 | Pubmed ID: 29166299
Have Clinical Trials Properly Assessed c-Met Inhibitors?
Trends in cancer 02, 2018 | Pubmed ID: 29458966
Tumor oxygenation and cancer therapy-then and now.
The British journal of radiology Jan, 2019 | Pubmed ID: 29513032
Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model.
Tumor & microenvironment , 2018 | Pubmed ID: 29658958
Stromal cells in breast cancer as a potential therapeutic target.
Oncotarget May, 2018 | Pubmed ID: 29805773
Stability and Mobility of Magnetic Nanoparticles in Biological Environments Determined from Dynamic Magnetic Susceptibility Measurements.
Bioconjugate chemistry 08, 2018 | Pubmed ID: 30011185
Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion.
Oncotarget Jan, 2019 | Pubmed ID: 30719213
Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running.
PloS one , 2019 | Pubmed ID: 31050686
Axl signaling is an important mediator of tumor angiogenesis.
Oncotarget Apr, 2019 | Pubmed ID: 31080559
Prostate cancer cell growth characteristics in serum and prostate-conditioned media from moderate-intensity exercise-trained healthy and tumor-bearing rats.
American journal of cancer research , 2019 | Pubmed ID: 31105994
c-Src is required for hypoxia-induced metastasis-associated functions in prostate cancer cells.
OncoTargets and therapy , 2019 | Pubmed ID: 31190858
Cathepsin L secretion by host and neoplastic cells potentiates invasion.
Oncotarget Sep, 2019 | Pubmed ID: 31565189
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.
Cancers Jul, 2020 | Pubmed ID: 32660000
Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics.
Tissue engineering. Part A 04, 2021 | Pubmed ID: 33059528
Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling.
Clinical & experimental metastasis 06, 2021 | Pubmed ID: 33791875
Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices.
Journal of bone oncology Jun, 2021 | Pubmed ID: 33912384
Normal tissue and tumor microenvironment adaptations to aerobic exercise enhance doxorubicin anti-tumor efficacy and ameliorate its cardiotoxicity in retired breeder mice.
Oncotarget Aug, 2021 | Pubmed ID: 34504647
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
International journal of molecular sciences Sep, 2021 | Pubmed ID: 34576116
Qin Luo*,1,
Miao Huang*,2,
Chenyu Liang2,
Justin Zhang3,
Gaoming Lin1,
Sydney Yu1,
Mai Tanaka4,5,
Sharon Lepler4,5,
Juan Guan5,6,7,
Dietmar Siemann4,5,
Xin Tang2,5
1Department of Electrical and Computer Engineering, Herbert Wertheim College of Engineering, University of Florida,
2Department of Mechanical and Aerospace Engineering, Herbert Wertheim College of Engineering, University of Florida,
3Department of Electrical and Computer Engineering, University of California,
4Department of Radiation Oncology, College of Medicine, University of Florida,
5UF Health Cancer Center, University of Florida,
6Department of Physics, College of Liberal Arts and Sciences, University of Florida,
7Department of Anatomy and Cell Biology, College of Medicine, University of Florida
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved